Thomas Gerstberger

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors.

Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors.

Journal: Communications chemistry

Published: November 06, 2025

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.

Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy.

Journal: Journal of medicinal chemistry

Published: July 25, 2025

Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays.

Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays.

Journal: Journal of medicinal chemistry

Published: July 15, 2024

Confounding Factors in Targeted Degradation of Short-Lived Proteins.

Confounding Factors in Targeted Degradation of Short-Lived Proteins.

Journal: ACS chemical biology

Published: July 03, 2024

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders.

Drugit: crowd-sourcing molecular design of non-peptidic VHL binders.

Journal: Nature communications

Published: August 16, 2023

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments.

Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments.

Journal: ChemMedChem

Published: December 16, 2022

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor.

Journal: Journal of medicinal chemistry

Published: October 27, 2022

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.

Journal: Nature communications

Published: March 02, 2022

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.

Journal: Nature cancer

Published: July 27, 2021

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

Journal: Journal of medicinal chemistry

Published: March 15, 2021

Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.

Reply to Tran et al.: Dimeric KRAS protein-protein interaction stabilizers.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 13, 2020

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.

Journal: Cancer discovery

Published: February 06, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026